Literature DB >> 15820265

Treatment guidelines for bipolar disorder: a critical review.

K N Fountoulakis1, E Vieta, J Sanchez-Moreno, S G Kaprinis, J M Goikolea, G S Kaprinis.   

Abstract

INTRODUCTION: The development of treatment guidelines emerged as an important element so as to standardize treatment and to provide clinicians with algorithms, which would be able to carry research findings to the everyday clinical practice. MATERIAL AND
METHOD: The MEDLINE was searched with the combination of each one of the key words 'mania', 'manic', 'bipolar', 'manic-depression', 'manic-depressive' with 'treatment guidelines'.
RESULTS: The search was updated until March 1st, 2004 and returned 224 articles. Twenty-seven papers concerning the publication of treatment algorithms were traced. DISCUSSION: Despite supposedly being evidence-based, guidelines for the treatment of bipolar disorder vary significantly across committees or working groups. Overall, however, at the first stage of the mania/hypomania algorithm, monotherapy with lithium, divalproex sodium or olanzapine is generally recommended. At latter stages combination therapy is strongly recommended. It is clearly stated that in bipolar depression antidepressants should be used only in combination with antimanic agents in order to avoid switching of phases. During the maintenance phase all patients should receive antimanic agents, while some may need the addition of antidepressants. The most recent guidelines emphasize the use of atypical antipsychotics for mania and lamotrigine for depression. The main problem with guidelines is that they are rapidly outdated and that the evidence base relies mainly on registration monotherapy trials that hardly reflect treatment in routine clinical conditions.
CONCLUSION: Treatment guidelines may be useful to avoid non-evidence-based treatment decisions, but they are quickly out-of-date and may not fully apply to the clinical setting. The more recent guidelines point the value of atypical antipsychotics, lithium, and valproate in the treatment of mania; the role of lithium, lamotrigine, and olanzapine as options for maintenance therapy; and the scarcity of options for the treatment of bipolar depression. Psychoeducation is also supported by most guidelines as an adjunctive treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820265     DOI: 10.1016/j.jad.2005.01.004

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  29 in total

1.  A 4-year study of lithium intoxication reported to the Czech Toxicological Information Centre.

Authors:  Martina Krenová; Daniela Pelclová
Journal:  Pharm World Sci       Date:  2006-11-17

2.  C-fos expression in the rat brain following lithium chloride-induced illness.

Authors:  Justin St Andre; Katie Albanos; Steve Reilly
Journal:  Brain Res       Date:  2007-01-03       Impact factor: 3.252

3.  Psychiatry: from interest in conflicts to conflicts of interest.

Authors:  Eduard Vieta
Journal:  World Psychiatry       Date:  2007-02       Impact factor: 49.548

4.  Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.

Authors:  Jay D Amsterdam; Justine Shults
Journal:  J Clin Psychopharmacol       Date:  2010-06       Impact factor: 3.153

Review 5.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 6.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

7.  Treating bipolar disorder in the primary care setting: the role of aripiprazole.

Authors:  J Sloan Manning; Susan L McElroy
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

8.  Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review.

Authors:  Konstantinos N Fountoulakis; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2009-07-27       Impact factor: 3.455

9.  Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.

Authors:  Barbara Monti; Valentina Gatta; Francesca Piretti; Simonetta S Raffaelli; Marco Virgili; Antonio Contestabile
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

10.  Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis.

Authors:  Konstantinos N Fountoulakis; Xenia Gonda; Eduard Vieta; Frank Schmidt
Journal:  Ann Gen Psychiatry       Date:  2009-12-31       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.